Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IFNs and STATs in innate immunity to microorganisms
Thomas Decker, … , Mathias Müller, Pavel Kovarik
Thomas Decker, … , Mathias Müller, Pavel Kovarik
Published May 15, 2002
Citation Information: J Clin Invest. 2002;109(10):1271-1277. https://doi.org/10.1172/JCI15770.
View: Text | PDF
Perspective

IFNs and STATs in innate immunity to microorganisms

  • Text
  • PDF
Abstract

Authors

Thomas Decker, Silvia Stockinger, Marina Karaghiosoff, Mathias Müller, Pavel Kovarik

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
JAK-STAT signal transduction in response to type I and type II IFNs. Upo...
JAK-STAT signal transduction in response to type I and type II IFNs. Upon binding of ligand, IFN receptor–associated Janus kinases (JAKs) are activated and phosphorylate receptor chains on tyrosine. Cytoplasmic signal transducers and activators of transcription (STATs) bind to the phosphorylated receptors with their SH2 domains. JAKs associated with the type I IFN receptor (IFNAR) then phosphorylate STAT1 and STAT2 on tyrosine, causing the formation of predominantly STAT1-STAT2 heterodimers, and of STAT1 homodimers. IFN-γ receptor–associated (IFNGR-associated) JAKs phosphorylate STAT1, leading to the formation of STAT1 homodimers. STAT dimers translocate to the cell nucleus. Thereafter, STAT1-STAT2 heterodimers associate with a third protein, IRF9, and bind one class of type I IFN response elements, the ISRE, whereas STAT1 homodimers activate gene expression by binding to another class of IFN response elements, the GAS.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts